Fig. 2

LOX/LOXL2 overexpression reduces supply of 4T1 tumors. a Western blot analysis of LOX and LOXL2 expression levels after stable transduction with lentiviral particles pLVX-luc-LOX, pLVX-luc-LOXL2, and the control particles pLVX-luc. b Growth curve of breast carcinomas (BCAs) generated by implantation of 4T1-pLVX-luc, 4T1-pLVX-luc-LOX, and 4T1-pLVX-luc-LOXL2 cells. c Weight of 4T1 control and 4T1 LOX/LOX2 OE BCAs 27 days after implantation. d Histological analysis of H&E-stained 4T1 and 4T1 LOX/LOX2 OE tumors reveals increased necrosis in the central region of 4T1 BCAs after LOX/LOXL2 OE. NA necrotic area, SB: 1000 µm. e Ki-67 staining at the front of 4T1 control and 4T1 LOX/LOX2 OE BCAs. SB: 100 µm. f Analysis of PSR-stained 4T1 control and 4T1 LOX/LOX2 OE BCAs shows increased staining for fibrillar collagens in 4T1 tumors after LOX/LOXL2 OE. SB: 100 µm. g Photometric quantification of Sirius Red bound to collagen in tissue sections. Values are normalized against total protein content. (n = 6). h Quantification of doxorubicin accumulated in 4T1 control and 4T1 LOX/LOX2 OE BCAs 2 h post injection (n = 9). i Quantification of H33342 tissue penetration in 4T1 control and 4T1 LOX/LOX2 OE BCAs. Distance of detectable H33342 staining from vessel surfaces in 3D confocal micrographs was measured (n = 4). Error bars: ±SEM. * indicates statistical significance vs. control, *P < 0.05, **P < 0.01